REXULTI Trademark

Trademark Overview


On Thursday, February 27, 2025, a trademark application was filed for REXULTI with the United States Patent and Trademark Office. The USPTO has given the REXULTI trademark a serial number of 79420940. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, April 3, 2025. This trademark is owned by Otsuka Pharmaceutical Co., Ltd.. The REXULTI trademark is filed in the Medical Instrument Products category with the following description:

Medical apparatus and instruments for use in diagnosing and monitoring vital signs of patients with psychiatric and neurological disorders and diseases, dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; injection devices for medical purposes; syringes and needles for injections and medical purposes; apparatus and instruments for diagnostic purposes, namely, integrated medical systems comprising m...
rexulti

General Information


Serial Number79420940
Word MarkREXULTI
Filing DateThursday, February 27, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateThursday, April 3, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesMedical apparatus and instruments for use in diagnosing and monitoring vital signs of patients with psychiatric and neurological disorders and diseases, dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; injection devices for medical purposes; syringes and needles for injections and medical purposes; apparatus and instruments for diagnostic purposes, namely, integrated medical systems comprising medical diagnostic imaging apparatus and software sold as a unit therewith for managing, measuring, monitoring, assessing, controlling, collecting, storing, and examining patient and client data and information captured by the medical system in web-based physical, psychological and neurological examinations conducted at a distance and at a clinic; medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systems

Classification Information


International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateTuesday, April 8, 2025
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOtsuka Pharmaceutical Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events


Event DateEvent Description
Thursday, April 3, 2025SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Tuesday, April 8, 2025LIMITATION FROM ORIGINAL APPLICATION ENTERED
Wednesday, April 9, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, April 9, 2025APPLICATION FILING RECEIPT MAILED